(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Under the agreement, Gilead will supply enough doses of its Lenacapavir drug to reach up to two million people over three ...

Only 17,000 Ugandans to benefit from $1.1m Global Fund support as officials warn of high demand for long-acting prevention ...

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

The National Agency for the Control of AIDS (NACA) is set to host a high-level meeting to deliberate on sustainable ...

Gilead Sciences (NasdaqGS:GILD) recently announced a partnership with the Global Fund to supply lenacapavir for HIV ...

The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...

A pivotal moment in the fight to end AIDS -- ensuring lifesaving innovation reaches those who need it most, wherever they live ...

Nigeria must take bold steps to ensure that HIV prevention, treatment, and support remain accessible and resilient, ...

Strategies that address population-specific concerns about medical mistrust and employ operational tactics, including staff ...

"There is now an urgent need for bolder and more realistic approaches to address HIV transmission among IPT students, similar ...